• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe newsletter
  • Search
  • Menu Menu
International Hospital
  • AI
  • Cardiology
  • Oncology
  • Neurology
  • Genetics
  • Orthopaedics
  • Research
  • Surgery
  • Innovation
  • Medical Imaging
  • MedTech
  • Obs-Gyn
  • Paediatrics

Archive for category: E-News

E-News

‘Capture the Fracture’ provides guidance for global efforts to prevent secondary fractures

, 26 August 2020/in E-News /by 3wmedia

Fragility fractures due to osteoporosis are a major cause of disability or premature death in older adults. Those at highest risk are patients who have already suffered one fragility fracture; they are at twice the risk of suffering a future fracture compared to others who have not fractured.
Nevertheless health care systems around the world are failing to identify and treat these patients, leaving them exposed to debilitating and life-threatening secondary fractures.
Based on evidence from numerous global studies, a new report, ‘Capture the Fracture: A Best Practice Framework and Global Campaign to Break the Fragility Fracture Cycle’ (1), sets 13 achievable standards for best practice in implementing fracture liaison services (FLS) worldwide, in a broad range of health-economic environments.
The report has been published in the peer-reviewed journal ‘Osteoporosis International’ and is endorsed by the International Osteoporosis Foundation (IOF) Committee of Scientific Advisors. It is available at link.springer.com/article/10.1007/s00198-013-2348-z
Fracture Liaison Systems help reduce the burden of fragility fractures:
Professor Cyrus Cooper, Chair of the IOF Committee of Scientific Advisors (CSA) emphasized the importance of systematic and coordinated secondary prevention care: ‘Coordinator-based FLS have been shown to close the gap in secondary fracture prevention care, ensuring that fragility fracture sufferers receive appropriate assessment and intervention to reduce future fracture risk.’
The best practice framework sets the foundation for ‘Capture the Fracture’, a multi-stakeholder initiative led by the International Osteoporosis Foundation. The initiative hopes to drive change so that secondary fracture prevention becomes a reality around the world.
The new initiative aims to:
 

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:532020-08-26 14:41:55‘Capture the Fracture’ provides guidance for global efforts to prevent secondary fractures

Antimicrobial resistance poses ?catastrophic threat?, says Chief Medical Officer

, 26 August 2020/in E-News /by 3wmedia

Global action is needed to tackle the catastrophic threat of anti-microbial resistance, which in 20 years could see any one of us dying following minor surgery, England

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:532020-08-26 14:42:02Antimicrobial resistance poses ?catastrophic threat?, says Chief Medical Officer

IUD best treatment for heavy periods, major trial shows

, 26 August 2020/in E-News /by 3wmedia

The hormone-releasing Mirena coil intrauterine device (IUD) is a better treatment for heavy menstrual periods than other conventional medical approaches, according to results of a major clinical trial led by scientists from the Universities of Nottingham and Birmingham.
 
The findings of the ECLIPSE study, funded by the National Institute for Health Research (NIHR) are widely expected to change standard clinical practice.

Heavy periods, or menorrhagia, affect the lives of large numbers of women aged 25-50 years, accounting for many GP consultations and 20 per cent of gynaecological referrals in the UK. Yet to date there has been limited evidence to help women and doctors make informed choices about treatments.

The ECLIPSE trial compared the clinical effectiveness of the levonorgestrel-releasing intrauterine system (also known as LNG-IUS or the Mirena contraceptive coil) with other medical treatments on offer in primary care.
 
A total of 571 women, consulting their GPs for heavy menstrual bleeding, agreed to be randomly assigned to LNG-IUS or to another standard medical treatment, such as tranexamic acid, mefanamic acid, combined estrogen and progestogen or progestogen only.
 
Over two years, patient reported outcomes improved more with LNG-IUS than with other treatments, including women

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:532020-08-26 14:42:10IUD best treatment for heavy periods, major trial shows

Benefit of PET or PET/CT in oesophageal cancer is not proven

, 26 August 2020/in E-News /by 3wmedia

The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic and prognostic accuracy, it also remains unclear whether these diagnostic techniques can detect the spreading of tumours better than conventional diagnostics. This is the conclusion of the final report of the German Institute for Quality and Efficiency in Health Care (IQWiG).
About 4800 men and 1400 women are newly diagnosed with oesophageal cancer in Germany each year. The average age of disease onset is 65 years. The 5-year survival rate in Germany is at most 20%; this means that 5 years after diagnosis, at best 20 of 100 affected patients are still alive.
Many experts assume that an examination using PET or PET/CT, alone or in combination with other methods, is better able to evaluate how far a tumour has spread (staging) and whether it has responded to treatment (restaging). In addition, better detection of tumour recurrence ought to be possible. The desired goal: the more exactly it is known how advanced the tumour is, the more precisely and successfully patients can be treated.
IQWiG therefore searched the international literature for studies that had examined the consequences of diagnostic interventions using PET or PET/CT with regard to whether they were accompanied by perceptible improvements for patients, for example, whether they increased their chances of survival or improved their quality of life, or spared them unnecessary operations or further diagnostic interventions.
However, the search for such direct comparative intervention studies was unsuccessful, so that the question regarding the patient-relevant benefit of PET or PET/CT in oesophageal cancer still remains to be answered.

IQWiG also searched for studies in which the diagnostic accuracy and prognostic power of PET or PET/CT was compared with other examination methods.
19 studies directly compared test accuracy of PET and CT
A total of 48 studies were relevant for diagnostic and prognostic accuracy, of which most examined the accuracy of primary staging, that is, the classification of tumour stages before the start of treatment.

19 studies directly compared PET with CT. However, conclusions in favour of one or the two techniques cannot be drawn, as either no statistically significant difference was shown or the data could not be interpreted with sufficient certainty.
Too few studies are so far available that directly compared PET or PET/CT with other diagnostic techniques and investigated treatment response (restaging) or diagnosis and prognosis of tumour recurrence. A reliable conclusion on the diagnostic and prognostic accuracy of PET or PET/CT in restaging or recurrence diagnostics is therefore not possible.
In particular the potential advantage of PET and PET/CT, which visualise metabolic activity, remains unclear versus morphologic imaging techniques such as CT or magnetic resonance imaging, which display anatomical structures.
IQWiG published the preliminary results in the form of the preliminary report in May 2012 and interested parties were invited to submit comments. At the end of the commenting procedure, which included an oral scientific debate including parties who had submitted comments, the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee (G-BA), in June 2013. The written comments were published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.
The German-language executive summary provides an overview of the background, procedure and further results of the report.

An English-language executive summary will be available soon. If you would like to be informed when the English document is available, please send an e-mail to

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:33Benefit of PET or PET/CT in oesophageal cancer is not proven

Engineers develop novel method to increase lifespan of joint replacements

, 26 August 2020/in E-News /by 3wmedia

Researchers at the University of Southampton have completed a project that will enable surgeons to fit joint replacements with longer, optimised lifespans. The MXL project uses computational modelling to define the mechanics of an artificial joint

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:40Engineers develop novel method to increase lifespan of joint replacements

Encouraging data from stem cell trial in stroke patients as plans for Phase II progress

, 26 August 2020/in E-News /by 3wmedia

Encouraging interim data from the world

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:48Encouraging data from stem cell trial in stroke patients as plans for Phase II progress

Electrical signatures of consciousness in the dying brain

, 26 August 2020/in E-News /by 3wmedia

The ‘near-death experience’ reported by cardiac arrest survivors worldwide may be grounded in science, according to research at the University of Michigan Health System.
University of Michigan researchers George Mashour, M.D., Ph.D. and Jimo Borjigin, Ph.D., provide the first scientific framework for near-death experiences.
Whether and how the dying brain is capable of generating conscious activity has been vigorously debated.
A U-M study shows shortly after clinical death, in which the heart stops beating and blood stops flowing to the brain, rats display brain activity patterns characteristic of conscious perception.
‘This study, performed in animals, is the first dealing with what happens to the neurophysiological state of the dying brain,’ says lead study author Jimo Borjigin, Ph.D., associate professor of molecular and integrative physiology and associate professor of neurology at the University of Michigan Medical School.
‘It will form the foundation for future human studies investigating mental experiences occurring in the dying brain, including seeing light during cardiac arrest,’ she says.
Approximately 20 percent of cardiac arrest survivors report having had a near-death experience during clinical death. These visions and perceptions have been called ‘realer than real,’ according to previous research, but it remains unclear whether the brain is capable of such activity after cardiac arrest.
‘We reasoned that if near-death experience stems from brain activity, neural correlates of consciousness should be identifiable in humans or animals even after the cessation of cerebral blood flow,’ she says.
Researchers analysed the recordings of brain activity called electroencephalograms (EEGs) from nine anaesthetised rats undergoing experimentally induced cardiac arrest.
Within the first 30 seconds after cardiac arrest, all of the rats displayed a widespread, transient surge of highly synchronised brain activity that had features associated with a highly aroused brain.
Furthermore, the authors observed nearly identical patterns in the dying brains of rats undergoing asphyxiation.
‘The prediction that we would find some signs of conscious activity in the brain during cardiac arrest was confirmed with the data,’ says Borjigin, who conceived the idea for the project in 2007 with study co-author neurologist Michael M. Wang, M.D., Ph.D., associate professor of neurology and associate professor of molecular and integrative physiology at the U-M.
‘But, we were surprised by the high levels of activity,’ adds study senior author anesthesiologist George Mashour, M.D., Ph.D., assistant professor of anesthesiology and neurosurgery at the U-M. ‘ In fact, at near-death, many known electrical signatures of consciousness exceeded levels found in the waking state, suggesting that the brain is capable of well-organised electrical activity during the early stage of clinical death.

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:36Electrical signatures of consciousness in the dying brain

Herding cancer cells to their deaths

, 26 August 2020/in E-News /by 3wmedia

An advanced tumour is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviours. This cellular heterogeneity is what makes advanced tumours so difficult to treat. An international team of scientists led jointly by Professors Colin Goding from the Ludwig Institute for Cancer Research who is based at the University of Oxford and Jos

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:43Herding cancer cells to their deaths

All hospitals should require drug, alcohol tests for physicians

, 26 August 2020/in E-News /by 3wmedia

To improve patient safety, hospitals should randomly test physicians for drug and alcohol use in much the same way other major industries in the United States do to protect their customers. The recommendation comes from two Johns Hopkins physicians and patient safety experts.
In addition, the experts say, medical institutions should take a cue from other high-risk industries, like airlines, railways and nuclear power plants, and mandate that doctors be tested for drug or alcohol impairment immediately following an unexpected patient death or other significant event.
‘Patients might be better protected from preventable harm. Physicians and employers may experience reduced absenteeism, unintentional adverse events, injuries, and turnover, and early identification of a debilitating problem,’ write authors Julius Cuong Pham, M.D., Ph.D., an emergency medicine physician at The Johns Hopkins Hospital, and Peter J. Pronovost, M.D., Ph.D., director of the Johns Hopkins Armstrong Institute for Patient Safety and Quality. Gregory E. Skipper, M.D., of the drug and alcohol treatment center Promises, in Santa Monica, CA. also contributed.
Pham, Pronovost and Skipper note that ‘mandatory alcohol-drug testing for clinicians involved with unexpected deaths or sentinel events is not conducted in medicine,’ even though physicians are as susceptible to alcohol, narcotic and sedative addiction as the general public. (A sentinel event is an incident which results in death or serious physical harm.)
The authors recommend in their commentary that hospitals take a number of steps as a model to address this overlooked patient safety issue. They are:
— Mandatory physical examination, drug testing or both, before a medical staff appointment to a hospital. This already occurs in some hospitals and has been successful in other industries.
— A program of random alcohol-drug testing.
— A policy for routine drug-alcohol testing for all physicians involved with a sentinel event leading to patient death.
— Establishment of testing standards by a national hospital regulatory or accrediting body. The steps could be limited to hospitals and their affiliated physicians at this time, since hospitals have the infrastructure to conduct adverse event analysis and drug testing, note the authors. Hospitals also have the governing bylaws to guide physician conduct and an existing national accrediting body, The Joint Commission, the authors add.
In cases in which a physician is found to be impaired, a hospital could ‘suspend or revoke privileges and, in some cases, report this to the state licensing board,’ the authors write. Impaired physicians would undergo treatment and routine monitoring as a condition for continued licensure and hospital privileges.
‘Patients and their family members have a right to be protected from impaired physicians,’ argue the authors in the JAMA commentary. ‘In other high-risk industries, this right is supported by regulations and surveillance. Shouldn

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:51All hospitals should require drug, alcohol tests for physicians

A heart of gold

, 26 August 2020/in E-News /by 3wmedia

Gold nanofibres in engineered heart tissue can enhance electrical signalling, TAU researchers find. Heart tissue sustains irreparable damage in the wake of a heart attack. Because cells in the heart cannot multiply and the cardiac muscle contains few stem cells, the tissue is unable to repair itself

https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png 44 200 3wmedia https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png 3wmedia2020-08-26 14:41:282020-08-26 14:41:31A heart of gold
Page 83 of 231«‹8182838485›»

Latest issue of International Hospital

April 2024

4 July 2025

Everdrone expands world-first medical emergency drone network in Sweden

4 July 2025

Wireless implant breakthrough offers personalised chronic pain relief

3 July 2025

EEG-powered brain computer interface enables finger-level robotic hand control

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign in for our newsletter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Media kit
    • Submit Press Release

Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Sign in for our newsletter

Free subscription